RCOR2 and cancer: Protein levels of CIITA and MHC-II molecules were also elevated in RCOR2-depleted cancer cells following IFN-γ treatment and in PyMT tumors, as shown by immunoblot, flow cytometry, and/or immunostaining assays (Figure 4J and Supplemental Figure 4, F–J).